Project Description

Company Description

Thermalin Diabetes is developing clinically superior, second-generation insulin analogs for the rapidly growing $12 billion insulin market.

Thermalin’s patent-pending compounds include rapid-, intermediate- and long-acting analogs. With patents expiring on existing analogs in the next three to four years, Thermalin looks to form partnerships with large pharmaceutical companies that wish to market superior, next-generation insulin therapies.

Industry Sector
Biomedical & Health Tech


JumpStart Investment
Evergreen Fund